
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Victoria, British Columbia - Sometimes what we accept as fact isn't actually reality. The truth in pediatric dermatology is turning out to be a bit different in some conditions than was taken for granted just a few years ago.






